colo_done

Latest Treatment Options in Colorectal Cancer and Breast Cancer

NOTE: The broadcast schedule for this program is complete.

If you have questions regarding your educational credit:

Contact the sponsor via e-mail or telephone 609-921-6622.

If you would like to obtain a copy of the certified monograph:

Please send an e-mail to the publisher.

Financial support for this program is provided by an unrestricted educational grant from Roche Laboratories Inc.

Moderator:

Robert Lynch, MD

Jackson, MS

Faculty:

Yehuda Z. Patt, MD: "Controversies and the Role of Oral Fluoropyrimidines in the Treatment of Colorectal Cancer"

Professor of Medicine

University of Texas

MD Anderson Cancer Center

Houston, TX

Daniel R. Budman, MD: "Latest Treatment Options for Metastatic Breast Cancer"

Professor of Clinical Medicine

New York University School of Medicine

New York, NY

This is a one-hour program. There will be three broadcasts:

1. Live Broadcast:

Wednesday, March 6, 2002, 1 PM Eastern

(12 Noon Central, 11 AM Mountain, 10 AM Pacific)

2. Rebroadcast:

Tuesday, March 12, 2002, 4 PM Eastern

(3 PM Central, 2 PM Mountain, 1 PM Pacific)

3. Rebroadcast:

Wednesday, March 20, 2002, 5 PM Eastern

(4 PM Central, 3 PM Mountain, 2 PM Pacific)

Accreditation:

Physicians: This activity has been planned and implemented in accordance with the essential areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Seton Hall University School of Graduate Medical Education, the American Academy of Continuing Medical Education, Inc. and VitalSigns Healthcare TV. Seton Hall University School of Graduate Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Seton Hall University School of Graduate Medical Education designates this CME activity for a maximum of 1 hour in Category 1 credit toward the American Medical Association Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Pharmacists: Independent Pharmacy Alliance, Inc. is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. Completion of this program provides for 1 hour (0.1 CEU) of continuing education credit. Participants must complete and submit a registration form and the program evaluation form in order to receive CE. Certificates of completion will be mailed within 4-6 weeks of the program. The program number for this symposium is 191-999-01-005-L/H01. There is no cost to attend this symposium.

Nurses: Application has been made for 1 contact hour to the Oncology Nursing Society's Approval Unit. The Oncology Nursing Society is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation.

Disclosure: It is the policy of Seton Hall University to ensure balance, independence, objectivity, and scientific rigor in all sponsored programs. All faculty participating in programs are expected to disclose to the program audiences any relationship with a manufacturer of any product or device discussed in their presentation.

Objectives: Participants should be able to:

Review clinical data available in colorectal cancer and breast cancer Discuss the latest therapeutic options in the medical treatment of these diseases

Target Audience: The primary target audience for this program is medical oncologists, physicians, pharmacists, nurses and other clinicians involved in the care of patients with colorectal or breast cancer.